Plus Therapeutics (STU:XMP0) 3-Year EBITDA Growth Rate : 44.50% (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Plus Therapeutics 3-Year EBITDA Growth Rate?

Plus Therapeutics's EBITDA per Share for the three months ended in Sep. 2024 was €-0.30.

During the past 3 years, the average EBITDA Per Share Growth Rate was 44.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 46.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 64.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Plus Therapeutics was 91.40% per year. The lowest was -23.20% per year. And the median was 46.10% per year.

Competitive Comparison of Plus Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Plus Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Plus Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Plus Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Plus Therapeutics's 3-Year EBITDA Growth Rate falls into.

Plus Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Plus Therapeutics (STU:XMP0) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Plus Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Plus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (STU:XMP0) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

PSTV:USA XMP0:Germany

Address

4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756

Website

https://www.plustherapeutics.com

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Plus Therapeutics Headlines

No Headlines